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Abstract
Background: Regular physical activity has important health benefits for children with type 1 diabetes mellitus
(T1DM), yet children and their parents face barriers to participation such as lack of self-efficacy or concerns around
hypoglycaemia. Multimedia interventions are useful for educating children about their health and demonstrate
potential to improve children’s health-related self-efficacy, but few paediatric clinics offer web-based resources as part
of routine care. The Steps to Active Kids with Diabetes (STAK-D) programme is an online intervention grounded in
psychological theory (social cognitive theory) and informed by extensive preliminary research. The aim of the
programme is to encourage and support safe engagement with physical activity for children with T1DM. The aim of
this research is to explore the feasibility of delivering the STAK-D programme to children aged 9–12 years with T1DM,
and to assess the feasibility of further research to demonstrate its clinical and cost-effectiveness.
Methods: Up to 50 children aged 9–12 years with T1DM and their parents will be recruited from two paediatric
diabetes clinics in the UK. Child-parent dyads randomised to the intervention group will have access to the
intervention website (STAK-D) and a wrist-worn activity monitor for 6 months. The feasibility of intervention and further
research will be assessed by rate of recruitment, adherence, retention, data completion and adverse events. Qualitative
interviews will be undertaken with a subsample of children and parents (up to 25 dyads) and health care professionals
(up to 10). Health outcomes and the feasibility of outcome measurement tools will be assessed. These include self-
efficacy (CSAPPA), objective physical activity, self-reported physical activity (PAQ), fear of hypoglycaemia (CHFS; PHFS),
glycaemic control (HbA1c), insulin dose, Body Mass Index (BMI), health-related quality of life (CHU9D; CHQ-PF28), health
service use and patient-clinician communication. Assessments will be taken at baseline (T0), 8 weeks (T1) and at
6-month follow-up (T2).
Discussion: The goal of this feasibility trial is to assess the delivery of STAK-D to promote physical activity
among children with T1DM, and to assess the potential for further, definitive research to demonstrate its
effectiveness. Results will provide the information necessary to design a larger randomised controlled trial and
maximise the recruitment rate, intervention delivery and trial retention.
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Background
Type 1 diabetes mellitus (T1DM) is one of the most
common chronic diseases in childhood [1]. It is a serious
illness, with rapidly increasing incidence and prevalence
[1–4] and age-specific mortality double that of the gen-
eral population [5]. In 2015, there were approximately
31,500 children under the age of 19 years with diabetes
in the UK, the vast majority with T1DM [6]. Diabetes
management is complex and costly in social, psycho-
logical and economic terms [7, 8]. Parents/carers1 of
preadolescent children with T1DM are generally respon-
sible for their child’s diabetes management and behav-
iours, making the transition from parental care to
independent self-management a unique experience for
children [9]. Treatment includes daily insulin injections,
a healthy diet with carbohydrate monitoring and regular
physical activity [10]. Poorly managed childhood dia-
betes can have significant lifelong consequences. Physical
activity has specific benefits for diabetes control [11], re-
ducing risk of diabetes complications and cardiovascular
disease [12], reducing overweight and benefiting mental
wellbeing [13]. Research has shown that children with
T1DM are less active than their peers [14–17] and
this can be associated with parental concerns about
hypoglycaemia [18] and the exposure of chronically ill
children to excessive fatigue [19].
Interventions to increase physical activity in paediatric
T1DM have commonly focussed upon structured aer-
obic or resistance exercise training [11, 20]. These inter-
ventions work well for young people who are already
active but for those children who are less active, promot-
ing lifestyle physical activity (such as walking, active
play, etc.) may be more appropriate [21]. Consequently,
there is need for an intervention that encourages and
supports safe engagement with physical activity for chil-
dren with T1DM.
Our previous work highlights a need for theoretically-
informed interventions which include psychological ele-
ments (and outcomes) [11]. Our studies have shown that
parental fear of hypoglycaemia and children’s low confi-
dence for physical activity (self-efficacy) are important
barriers to being active for children with T1DM [18, 22].
Self-efficacy in particular is a critical element in increas-
ing and sustaining physical activity levels [21, 23]. Par-
ents have pointed to a lack of ‘digestible’ resources for
physical activity promotion and health care professionals
(HCPs) have similarly identified a lack of age-appropriate,
evidence-based resources [24]. Consequently, intervention
should be age-appropriate and build children’s self-
efficacy for physical activity which is essential to enable
sustained lifelong behavioural changes.
In the UK, the peak age for diagnosis of T1DM is be-
tween 10 and 14 years [25]. Interactive, multimedia in-
terventions may be useful health promotion tools with
children of this age, who are learning skills in self-
managing their condition. Our previous research shows
that HCPs support the concept of introducing inter-
active, multimedia resources focussed on behaviour
change into the clinical care of children [26]. Multimedia
interventions are useful for educating children about
their health, demonstrate potential to improve children’s
health-related self-efficacy, and could make them more
able partners in face-to-face communications with
HCPs [27].
Prior work has demonstrated that children with
T1DM favour web-based information [28] and that they
(irrespective of socioeconomic and ethnic background)
are comfortable with electronic media [29]. Similarly,
parents of this age group are receptive to the use of
novel technologies to help manage their child’s diabetes
[30]. Despite this, few paediatric clinics offer web re-
sources for physical activity promotion as part of routine
care, and technology-based interventions for children
with T1DM are scarce. Existing resources are not devel-
oped for this age group; they tend to focus on ‘sport’
rather than physical activity and active lifestyles; or
they focus primarily on the parent rather than the
child [29, 31–35]. Computer or web-based interven-
tions have shown to be feasible, acceptable [34, 35]
and can be effective [36] in promoting physical activity in
school-aged children. Consequently, there is potential for
a dedicated, interactive resource specifically promoting
physical activity in children with T1DM.
We have previously developed a theory-based physical
activity intervention for children with chronic conditions
called Steps to Active Kids (STAK) [21] which builds
self-efficacy for physical activity. This includes educa-
tional materials for parents and children, a physical ac-
tivity diary, group activity sessions and goal-setting
strategies. This feasibility study, known as the SKIP trial
(‘Supporting Kids with Diabetes in Physical activity’), will
adapt and test the feasibility of these materials for use by
children with T1DM [22] using an interactive, online
resource called STAK-D (Steps to Active Kids with
Diabetes). STAK-D is a web package delivering all as-
pects of STAK-D except the group activity sessions. It is
intended to promote safe physical activity, build self-
efficacy and reduce fear of hypoglycaemia. It includes
interactive elements, including child and parent zones,
physical activity tracking and goal-setting (with feed-
back), active role models, activity routines using video
demonstrations, and a message board. It is also a
medium through which parents and children can contact
a diabetes professional for advice on physical activity
with diabetes through an ‘Ask the Expert’ facility.
STAK-D is a complex intervention which has been
designed for implementation as an adjunct to clinical
care in T1DM management. It is targeted at children
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aged 9–12 years and their families. Targeting this age
range is appropriate since participants are likely to have
a level of independence commensurate with using
computer-based packages at home (98%) [37] with sup-
port from their parents. Also, intervention is beneficial
at this age since lifestyle behaviours which are adopted
preadolescence are more likely to be sustainable and,
therefore, to influence disease risk factors across the life
course [38].
The STAK-D programme combines educational (infor-
mation, physical activity guidance, safety information),
behavioural (physical activities and activity tracking) and
cognitive-behavioural (physical activity monitoring and
goal-setting) strategies to promote children’s self-efficacy
for physical activity. STAK-D draws upon social cogni-
tive theory constructs of self-efficacy and observational
learning [39]. The intervention targets children who
have barriers to physical activity and aims to promote
self-efficacy via observing role models, mastery experi-
ence and persuasion (via education). It provides general
advice around regular blood glucose monitoring (e.g. be-
fore, during and after physical activities and regularly
throughout the day) and healthy eating, which has been
approved by diabetes specialists, but it does not give
guidance on insulin dosage and administration or carbo-
hydrate counting. For this, families are encouraged to
contact their clinical team, either using the ‘Ask the
Expert’ element of the website or at their standard clinic
appointments.
In addition to the website, STAK-D utilises a wrist-
worn activity monitor (PolarActive; Polar Electro Inc.,
Lake Success, NY, USA) to encourage activity monitor-
ing and goal-setting behaviours. The site is password-
protected and can currently only be accessed by research
participants and personnel.
Rationale
As there is no published data for the efficacy of a theory-
based, online physical activity intervention for preadoles-
cent children with T1DM, this research marks an import-
ant first stage in the development of an evidence base.
This study will explore how feasible it is to deliver the
STAK-D programme to promote self-efficacy for physical
activity in this population, and its findings will inform the
decision to run a future definitive clinical trial.
Aim
The main aim of this study is to establish the feasibility
of undertaking a definitive trial to investigate the effect-
iveness of STAK-D. The definitive trial will be deemed
feasible if it is demonstrated that we can successfully
identify, recruit and retain patients with T1DM, and the
proposed study design and intervention are considered
acceptable by patients, parents and clinicians.
Study objectives
Primary research objective
The main objectives are to accomplish the following:
(1) to estimate the likely recruitment rate of children
and their parents, (2) to assess the willingness of the
clinical staff to recruit participants, (3) to assess the
willingness of eligible participants to be randomised,
(4) to assess adherence and compliance to different
elements of the intervention (including wrist-worn ac-
tivity monitors), (5) to examine potential adverse ef-
fects of the intervention, (6) to test collection of
health, clinical and economic outcome measures with
the aim of informing the larger trial, (7) to explore
reasons for loss to follow-up and (8) to access the
overall acceptability of the intervention.
Secondary research objectives
A secondary research objective is to estimate the vari-
ability of self-efficacy for physical activity scores (e.g.
pre-intervention to post-intervention change) and other
outcome measures in order to inform decisions about
primary and secondary outcomes for the larger-scale
randomised control trial (RCT) and associated sample
size calculation.
Methods
The protocol has been prepared according to Standard
Protocol Items: Recommendations for Interventional
Trials-Extension for Newborns, Children, and Adolescents
(SPIRIT-C) [40]. For the completed checklist, see
Additional file 1.
Study design
This study is a 6-month randomised feasibility trial. It is
a two-arm, individually randomised, controlled feasibility
trial comparing the use of the STAK-D programme to
usual clinical care. A mixed-method process evaluation
will be ongoing and explore rate of recruitment, adher-
ence (pattern of intervention use), retention, data com-
pletion and adverse events. Qualitative interviews with
key stakeholders (children, parents and HCPs) will explore
satisfaction with the intervention and identify necessary
improvements prior to proceeding to a definitive trial.
Study setting
Participants will be recruited from two paediatric T1DM
clinics in the UK. The intervention will be delivered via
a website that can be accessed by participants remotely
(at home) via multimedia devices.
Selection of subjects
Inclusion criteria
Children aged 9–12 years who have been diagnosed with
T1DM for at least 3 months and their parents will be
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eligible to take part in the study. They must be able to
understand spoken and written English.
Children and parents eligible for the qualitative
process evaluation will be those who have been directly
involved with the intervention; eligible HCPs will have
been directly involved in the clinical care of children in
the intervention arm of the study and be familiar with
the research processes; all must consent/assent to being
involved in an interview.
Exclusion criteria
Children who meet at least one of the following criteria
will be excluded: (1) recurrent hypoglycaemia (blood
glucose level below 4 mmol/l occurring at least daily) or
consultant concern indicating poorly managed diabetes
(glycosylated haemoglobin (HbA1c) level >80 mmol/mol
and/or testing fewer than four blood glucose levels/day
on a downloadable meter) and (2) lacking the mental
capacity to decide to take part in the study and to par-
ticipate in it (based on the clinical team’s judgement in
accordance with the Mental Capacity Act 2005 Code of
Practice 2007).
Interventions
Active intervention
The intervention will be delivered to participants rando-
mised to the intervention arm by a health psychology re-
searcher. The researcher will provide parents and
children with login details for the STAK-D website, and
conduct face-to-face orientation training with them to
demonstrate the website components and assist them in
setting physical activity goals. They will be encouraged
to use the website for the duration of the study and for a
minimum of 6 weeks. The researcher will provide the
child with a PolarActive watch, together with verbal and
written instructions for its use and guidance on how the
activity data will be downloaded. All children in the
intervention group will be provided with a supplemen-
tary leaflet signposting them to local events, services and
facilities where they can engage in physical activity.
Children will receive full access to all the intervention
components for 8 weeks (Table 1). After 8 weeks until
the 6-month follow-up (T1 to T2), participants will con-
tinue to have access to the website (Kid Zone and Parent
Zone) and the PolarActive activity monitor, but they will
no longer receive individualised feedback on their activ-
ity levels.
Control group
Participants in the control group will not receive the
STAK-D intervention, but will continue with usual clin-
ical care according to that available at the site from
which they were recruited. Both participating sites oper-
ate under the same general standardisation of care; they
both adhere to Global IDF/ISPAD Clinical Practice
Consensus Guidelines [41], NICE guidelines for clinical
care of diabetes in children and young people [42], and
the UK National Health Service (NHS) national diabetes
best practice tariff, which specifies requirements for the
service. Quantifying usual care with regards physical ac-
tivity is difficult, although our previous qualitative re-
search suggests that lifestyle physical activity advice is
limited in the current clinical care of children with
T1DM [18, 24]. Usual care at each site will be described
Table 1 Components, content and theoretical underpinning of the Steps to Active Kids with Diabetes (STAK-D) programme
Component Content Theoretical underpinning
Kid Zone (website) Physical activity information and advice, 5-a-day
activity target, activity tracking, goal-setting
Outcome expectations
Persuasion (education)
Self-regulation (goal-setting, self-monitoring)
Mastery experience
Street dance routine (website) 28 × 10-min dance sessions gradually developing
into a complete dance routine
Vicarious experience (role model)
Mastery experience
Social support
Goal-setting (website) Personalised goal-setting and goal feedback from
researchers via the website
Identifying facilitators and barriers to behaviour
change
Self-regulation (self-monitoring and goal-setting)
Social support
‘Ask the Expert’ (website) A way for children/parents to contact a health
care professional with questions about physical
activity with diabetes
Social support
Persuasion (education)
Messaging Board (website) An area where children/parents can post messages,
comments and questions to other children/parents
Social support
Vicarious experience
Physical activity monitor (PolarActive) Physical activity and step-count monitoring/tracking Self-regulation (self-monitoring and goal-setting)
Mastery experience
Parent Zone (website) Information and advice around physical activity Social support
Vicarious experience (role model)
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as part of this feasibility study following recommenda-
tions by Erlen et al. [43]; this will allow for accurate def-
inition of usual care in future trial design.
Outcome measures
Outcome measures will be completed at baseline (T0),
8 weeks (T1) and 6 months (T2).
Primary outcome measures
The primary outcome measures for the feasibility study
are as follows:
1. Recruitment rate
An estimate of the number of eligible patients and
likely uptake rate will be assessed. The response rate
for mailed invitation will be compared to clinic
(face-to-face) recruitment rates. Refusal rate and
reasons for nonparticipation will be assessed. This
will enable a prediction of recruitment rate, number
of sites and length of time needed to recruit the
required number of patients for a future trial. A
recruitment rate of between 25 and 40% would be
considered reasonable based on our previous
research [22] and similar studies [44, 45]
2. Adherence rate
Pattern of intervention use will be monitored to
assess fidelity of intervention delivery. We will
explore users’ activity by website and page visits,
more or less commonly used elements, and
engagement with goal-setting and activity tracking.
We will assess user satisfaction with STAK-D (e.g.
navigation, ease of use, technical issues) at 6 months.
Acceptable compliance will be defined as the child
using the online resources and tracking their daily
activity (using the PolarActive watch). Noncompliance
will be defined as the child’s failure to access the
STAK-D website and track their physical activity over
the intervention period
3. Retention rate
Retention will be defined as the number of
participants completing the STAK-D programme
including all scheduled follow-up data collection
(T0, T1 and T2) compared to the number started. A
retention rate of at least 70% at each time point
would be considered feasible based on our previous
research [22] and similar studies [44, 45]
4. Data completion rate
Completion of outcome measures will be recorded
at T0, T1 and T2 (complete and partial or
noncompletion with reasons, including time to
complete). Measures will be determined acceptable to
parents and children (in terms of literacy,
cognitive ability and capacity to understand) if
more than 70% are fully completed (indicating
quality data), and reported participant burden is
minimal.
The feasibility of gathering routinely collected clinic
data from patients’ electronic diabetes record
(height, weight, HbA1c level and insulin dosage) at
T0, T1 and T2 will be assessed. This will allow us to
ascertain the proportion of our sample with
complete clinical records, and whether records will
be accessible to our researchers at specified data
collection time points. Feasibility of collecting
observational data in this way will be determined if
more than 85% of the sample have complete clinical
records available
5. Adverse events
Any adverse events experienced as a result of
participation in the intervention will be recorded
and evaluated. Adverse events are defined as any
serious negative outcome resulting from the physical
activity undertaken as part of the STAK-D
programme. Severe hypoglycaemia, i.e., a blood
glucose level below 4 mmol/l requiring the help of
another person to treat it, will be considered an
adverse event in either group. Data from meter and
pump downloads combined (and meter downloads
alone for those patients not on insulin pump therapy)
will be used for identification of hypoglycaemic
episodes, as per usual care at our participating
sites. To determine the likelihood of adverse
events being associated with the physical activity
undertaken as part of the STAK-D programme, we
will record whether the frequency and/or severity of
hypoglycaemic episodes increased during the
intervention period. The occurrence of adverse
events related to the intervention will be assessed
and compared to the control group (see ‘Harms’
section for potential adverse events).
Qualitative interviews
At the 6-month follow-up (T2), child-parent dyads in
the intervention group and HCPs will be interviewed to
assess their experience of participating in the trial, the
acceptability of the intervention and their overall experi-
ence. All participants who drop out will be approached
for an interview. The interviews will explore: (1) the
willingness of participants to be randomised, (2) whether
children enjoyed the STAK-D programme or not, and
why, including how it made children feel, (3) children’s
satisfaction with the wrist-worn activity monitor
(PolarActive), (4) barriers to participation in the
STAK-D programme, including reasons for nonadher-
ence, (5) acceptability of the research processes in-
cluding reasons for attrition and missing data, (6)
whether parents and children thought that the interven-
tion was beneficial, useful and easy to incorporate into
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daily routine, (7) children’s and parents’ perceived reasons
for, and response to, any changes in outcomes, (8) willing-
ness of HCPs to be involved in recruitment, (9) willingness
of HCPs to receive and reply to emails from STAK-D
programme users (via the ‘Ask the Expert’ section on the
website), (10) suitability of the clinic setting for recruit-
ment and (11) whether the inclusion criteria were deemed
appropriate by patients, parents and HCPs.
Health care costs
Estimated costs relevant to recruitment, screening, inter-
vention implementation and follow-up will be calculated.
We will also estimate retrospectively the health care re-
source use and cost them at national rates.
Secondary outcome measures
The following standardised measures have adequate psy-
chometric properties and have been used in other stud-
ies with children of the same age range who have T1DM
[22] or other long-term conditions [21]. Our previous
research [22] and significant patient and public involve-
ment activities have indicated that the assessments may
take approximately 45–60 min to complete. The out-
comes measured at T0, T1 and T2 will be:
Child measures
I. Self-reported physical activity
Self-reported frequency of different types of
physical and sedentary activities will be assessed
with a 55-item physical activity questionnaire
(PAQ) [46] adapted from the full 80-item PAQ
[47]. The questionnaire refers to the previous 24 h
and children are asked to rate a range of activities,
on a three-point scale (none, a little, a lot) at three
time points (yesterday afternoon, last night, this
morning). Higher scores indicate greater frequency
of engagement in physical activity. The authors of
the PAQ reported good agreement between
questionnaire responses for PAQ and observed
activities [47]. Furthermore, combining interview
technique with probing activity in the recent past
is considered most likely to generate results that
correlate with objective measures of activity [48].
The 55-item PAQ has been found to discriminate
physical activity levels in children attending
paediatric outpatient clinics [46]
II. Self-efficacy for physical activity
Children’s self-efficacy for physical activity will be
measured using the Children’s Self-Perceptions of
Adequacy in, and Predilection for, Physical Activity
scale (CSAPPA) [49]. CSAPPA is a 20-item scale
to measure the self-perception of confidence in,
preference for, and enjoyment of physical activity.
CSAPPA is composed of three subscales: (1)
perceived adequacy (perceived ability to achieve
some level of successful with respect to being
physically active), (2) predilection toward physical
activity (preference for being active over being
sedentary when given the choice) and (3) enjoyment
of physical education class. The scale employs a
structured alternative choice format. Children are
asked to choose the option that best describes them
from pairs of statements about other children such
as, ‘Some kids can’t wait to play active games after
school’ and ‘Other kids would rather do something
else’ by indicating whether the sentence was either
‘sort of true for me’ or ‘really true for me’. Higher
scores for subscales indicate greater perceived
adequacy, predilection for, and enjoyment of
physical activity. The scale was designed by
Hay (1992) [49] for 9–16 year-olds and has
demonstrated high test-retest reliability and
strong predictive and construct validity
III. Fear of hypoglycaemia
Children’s fear of hypoglycaemia will be assessed
using the Child Hypoglycemia Fear Survey (CHFS)
[50]. CHFS is comprised of a 10-item behaviour
(B) subscale and a 15-item worry (W) subscale.
HFS-B items describe behaviours performed in
order to avoid hypoglycaemic episodes and/or
their negative consequences (e.g. by limiting
exercise or physical activity). HFS-W items ask
about specific concerns about hypoglycaemic
episodes (e.g. episodes occurring during sleep, or
having an accident). Higher scores indicate greater
fear of hypoglycaemia. Previous research has
indicated that the children’s HFS is a valid and
reliable measure of youth fear of hypoglycaemia
and that it significantly correlated with other
measures of anxiety [50]
IV. Health-related quality of life
Child Health Utility 9D (CHU9D) [51] is a health-
related quality of life measure for children aged 7–
17 years, which allows the calculation of quality-
adjusted life years (QALYs) for use in cost-utility
analysis. It consists of nine items (worry, sadness,
pain, tiredness, annoyance, school, sleep, daily
routine and activities) each represented by a single
question with five response options (scored 1–5).
Higher scores indicate better health-related quality
of life. The recall period is today/last night. The
CHU9D has demonstrated validity in paediatric
clinical populations [52]
V. Communication questionnaire
A short questionnaire developed specifically for
this study will be used to explore children’s
perceptions of the communication around physical
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activity they have with their diabetes team. It
contains two items and assesses children’s
perceptions of (1) frequency of physical activity
discussion (e.g. ‘In the last 6 months, have you
spoken to one of your diabetes doctors or nurses
about physical activity, exercise or sport?’ and, ‘If
yes, how many times (1–5+)?’) and (2) difficulty of
physical activity discussions (e.g. ‘talking to your
diabetes doctors and nurses about physical activity,
exercise or sport is…..?’ (5-point scale; really hard
to really easy))
VI. Objective physical activity
Physical activity will be measured objectively
using a PolarActive wrist-worn activity watch
(Polar Electro Inc., Lake Success, NY, USA) at
T0, T1 and T2 in intervention and control
group children. Wrist-worn activity monitors
have demonstrated acceptability and feasibility
among children with T1DM in previous research
[22]. The PolarActive device has shown to be
preferred by children aged 7–10 years compared
with other devices, and is associated with the
highest level of compliance [53]. Children will be
given the PolarActive watch for 7 days at each time
point, and start date (day of the week) will vary
according to recruitment date; we will monitor
patterns of physical activity over the data collection
period. Day 1 will be considered as a familiarisation
day to minimise potential reactivity and data
will be analysed if activity watches are worn for
at least 600 min on at least 3 days. Physical
activity will be measured as step counts and
average minutes in moderate-to-vigorous physical
activity per day
VII. Clinical outcome measures
These measures are routinely collected by the
diabetes health care team and, with consent, will
be taken from the child’s clinic notes. The
measurement that coincides most accurately with
the data collection period (T0, T1 and T2) will be
taken.
(a) Glycosylated haemoglobin (HbA1c) – as an
indication of diabetes control
(b) Insulin dosage – to explore changes as a
further indicator of diabetes control. Insulin
dosage is downloaded at standard clinic
appointments using diabetes management
software (e.g. Diasend/Carelink Diabetes
Management); we will assess the feasibility of
collecting this information from routine clinic
notes. Total daily insulin dose will be
recorded where possible, and we will examine
the practicality of collecting this data, and
subdividing it into basal and bolus doses
(c) Body composition – Body Mass Index (BMI)
will be calculated from height (cm) and
weight (kg)
The primary outcome to be used in a future large-
scale RCT is projected to be a change in self-efficacy for
physical activity as measured by the CSAPPA scale.
However, the choice of additional primary outcome
measures will be finalised after taking into account the
results of the feasibility study.
Parent measures
I. Participant characteristics
Parent’s demographic questionnaire will assess
ethnic background, family composition, parent(s)
education and parent(s) occupation. Date of the
child’s T1DM diagnosis, insulin delivery method
and method of glucose monitoring will also be
collected
II. Fear of hypoglycaemia
Parental fear of hypoglycaemia will be assessed
using the Parent Hypoglycemia Fear Survey
(PHFS) [50]. The PHFS is comprised of a 10-item
behaviour (B) subscale and a 15-item worry (W)
subscale. Higher scores indicate greater fear of
hypoglycaemia. This scale is the same as the
children’s version, the only difference is that it asks
about parental fear of hypoglycaemia. Research
shows that the PHFS can provide reliable self-
report of parental fear of hypoglycaemia [50]. It
also asks parents to report the number of severe
hypoglycaemic episodes that their child has
experienced in the past 12 months
III. Child health-related quality of life
This 28-item questionnaire (CHQ-PF28) assesses
physical and psychosocial wellbeing of the child,
from parent perspective, and can be used as a
proxy quality of life measure for health-utility
[54]. Higher scores indicate better health-related
quality of life. The CHQ-PF28 has demonstrated
reliability and validity in parents of children
aged 4–13 years [54]
IV. Additional self-reported items
Additional items self-reported by parents (‘follow-
up questionnaire’) will include: (1) number of
additional contacts with the diabetes team other
than routine clinic visits in the last 6 months, (2)
number of hospital admissions other than routine
clinic visits in the last 6 months, (3) days off school
in the last 6 months, (4) additional medications in
the last 6 months and (5) perceived frequency of
communication about physical activity in
consultations with the diabetes health care team
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HCP measures
I. Clinician-patient communication
A nine-item clinician-patient communication
questionnaire has been developed specifically for
this study and will be used to explore HCPs’ per-
ceptions of the communication around physical
activity they have with their patients. It aims to
assess (1) how often clinicians have discussed
physical activity with their patients and (2) how
clinicians feel about talking about physical activity
based on how much they agree with statements
(e.g. ‘I am able to talk to children and their parents
about physical activity.’)
Participant timeline
Figure 1 shows a flow chart of study processes. Table 2
shows the assessments at each time point.
Sample size
The sample size will be adequate to estimate the critical
parameters (e.g. recruitment rate) to the necessary
Fig. 1 Flow diagram of the study. CHFS Child Hypoglycaemia Fear Survey, CHQ Child Health Questionnaire, CHU9D Child Health Utility Instrument,
CSAPPA Children’s Self-Perceptions of Adequacy in, and Predilection for, Physical Activity scale, HCP health care professional, PAQ Physical Activity
Questionnaire, PHFS Parent Hypoglycaemia Fear Survey, Q questionnaire, RCT randomised controlled trial, STAK-D Steps to Active Kids with Diabetes
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degree of precision and to provide key information on
the feasibility of the intervention. There are approxi-
mately 170 patients in the specified age range across
both recruitment sites, prior to exclusions. We will tar-
get the recruitment of 50 child-parent dyads (approxi-
mately five per month over 9–10 months). We envisage
this to be achievable since previous studies indicate a
40–50% response rate with similar populations [22, 55]
and our selected feasibility study sites currently have re-
cruitment rates exceeding 100% for NIHR-adopted stud-
ies. Recruitment of a minimum of 33 child-parent dyads
(40%) would be deemed necessary to progress to full
trial; should recruitment be problematic a remedial act
will be to revise inclusion criteria to include age range
8–13 years. At T2, up to 25 child-parent dyads and up
to 10 HCPs will take part in interviews.
Table 2 Study assessments at specific time points
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Recruitment
Potential participants will be recruited from paediatric
diabetes clinics at the two hospital sites. They will be
identified and approached by a member of the clinical
team via a postal invitation pack (including letter,
Participant Information Sheets (PIS) and Expression of
Interest (EOI) Form). Children will receive a child-
friendly version of the PIS. If the child and parent are
willing to hear more about the study, they will return
the EOI to the research team, and will be introduced to
the researcher at their next clinic appointment for a de-
tailed discussion about the study. At this prestudy
screening meeting, consent will be received, baseline
data collected and randomisation performed. Partici-
pants will be randomised after baseline data has been
collected. The researcher and/or principal investigator
will receive written informed consent from the parent
and written informed assent from the child prior to the
participant undergoing any research procedures. There
must be mutual agreement between the child and parent
for the child to participate.
Assignment of interventions
Sequence generation
Consented participants will be individually randomised
with a 1:1 allocation to receive either the intervention or
usual care; no participant will receive less than standard
care. The allocated treatment will be determined using
the ‘Sealed Envelope Company’ randomisation service
[56]. After receiving consent and assent, and collection
of baseline data, the researcher will send an SMS text
message to the ‘Sealed Envelope Company’, which will
automatically randomise the participant to the interven-
tion or control group.
Blinding
Neither participants nor the researchers delivering the
intervention can be blinded due to the nature of the
intervention. Wherever possible, the data analysts (e.g.
statistician) will be blinded to treatment allocation. The
follow-up assessor may not be blinded given resource
constraints.
Data collection, management and analysis
Data collection methods
Participants will have six visits for data collection. Visits
will take place at either the child’s usual paediatric dia-
betes clinic or another mutually convenient location (e.g.
the participants’ home) depending on parent preference,
and preferred locations for data collection will be re-
corded. Children and parents will complete the assess-
ments at visits 1 (baseline/T0), 3 (T2) and 5 (T3).
Children will be assessed for self-reported physical activ-
ity (PAQ), self-efficacy for physical activity (CSAPPA
scale), fear of hypoglycaemia (CHFS), health-related
quality of life (CHU9D), clinician-patient communica-
tion and objective physical activity (PolarActive). As
close to visits 1, 3 and 5 as possible, the researcher will
ask the clinician for clinical data from the participants’
clinical records (height, weight, HbA1c level and insulin
dosage). Parents will be assessed for demographics, fear
of hypoglycaemia (PHFS), child’s quality of life (CHQ-
PF28) and additional self-reported items. One week after
visits 1, 3 and 5 (at visits 2, 4 and 6), data from the activ-
ity watch will be downloaded. Health care professionals
drawn from the paediatric diabetes teams at the study
sites will be asked to complete a clinician-patient com-
munication questionnaire at T0, T1 and T2.
At visit six, all child-parent dyads in the intervention
group will be invited to participate in single exploratory
interview as part of the process evaluation. All partici-
pant dyads who have dropped out of the study will be
invited to interview (at the point when they leave the
study). For practical reasons child and parent will be
interviewed together with questions/topics directed to
each as appropriate. Interviews will be undertaken face-
to-face at a time and venue convenient to the family.
Up to 10 HCPs who have been directly involved in the
care of children who have received the intervention
(including all those listed on each site file delegate log)
will be interviewed at the end of the study to gain their
perspective upon STAK-D delivery and the research pro-
cesses. Interviews with HCPs will be carried out in per-
son or over the telephone and will be recorded, with
permission from the interviewee. In particular, their will-
ingness to identify and approach patients, their opinion
about patient randomisation, and their comments upon
delivering and supporting STAK-D (specifically whether
they referred to STAK-D in their consultations) will be
considered. During these interviews the integration of
STAK-D with clinical practice and other NHS systems
will be explored. Interviewees will be drawn from the
paediatric diabetes teams at the study sites, and the sam-
ple will be constructed to reflect the range of professions
that is involved the care of children with T1DM who
have been exposed to the intervention. Wherever pos-
sible, individuals refusing to participate in the study will
be asked their reason(s) for nonparticipation.
Data management
Standard procedures following the Data Protection Act
(1998), the NHS Code of Confidentiality, and Good
Clinical Practice (GCP) will be implemented throughout
the study.
Statistical methods
Primary endpoint: feasibility Descriptive statistics will
be used to describe the sample characteristics and rates
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of recruitment, retention, completion and adherence
(frequencies, percentages, means and standard devia-
tions or medians and interquartile range). Adverse
events will be reported descriptively.
All interview data will be recorded digitally, tran-
scribed in full, anonymised, and handled using the
NVivo software package (QSR International Pty Ltd.,
2014). Following the conventions of framework analysis
[57] a pragmatic analytic framework will be constructed
and all interview data charted against this. The frame-
work will consist of two analytic matrices (one to ad-
dress STAK-D delivery, one to address trial design)
which will be structured to aid identification of elements
which worked well and those which require further
adaptation prior to a larger clinical trial. Interviews with
parent(s), children and HCPs will be analysed using the-
matic analysis. A minimum of two random transcripts
will be re-coded by an independent researcher to ensure
consistency.
Secondary endpoint: effect Effectiveness outcomes will
be described at each time point using descriptive and in-
ferential methods for categorical, continuous and/or or-
dinal health outcome measures using an intention-to-
treat approach, although imputation of missing outcome
data will not be performed for the primary analysis as
this is a feasibility study. Reasons for missing data will
be documented, and missing data will be quantified. In-
ferential analysis of outcomes will be presented as 95%
confidence intervals. Exploratory modelling will be used
to investigate factors found to be, or assumed to be, re-
lated to intervention effectiveness outcomes. Data will
be analysed using the Statistical Package for Social
Sciences (SPSS Inc., Chicago, IL, USA) and Stata
(StataCorp, College Station, TX, USA). The level of stat-
istical significance will be set at 5% for the primary out-
come measures. A detailed Statistical Analysis Plan will
be written by the statistician, in consultation with the re-
search team, prior to analysis. Continuous variables will
be reported by descriptive statistics (nonmissing sample
size, mean, standard deviation, median, maximum and
minimum). Categorical variables will be summarised
using frequencies and percentages. The descriptive sta-
tistics from the selected primary outcomes will inform
the sample size calculation of the main RCT.
Monitoring
Data monitoring Given the small scale of this feasi-
bility trial and the low risk of harm, an external Data
Monitoring Committee (DMC) will not be needed
and an interim analysis will not be performed. The
researchers recruiting, implementing, and assessing
the intervention will update the research team monthly
about the study progress.
Auditing Monitoring of trial data will include confirm-
ation of informed consent; source data verification; data
storage and data transfer procedures; local quality con-
trol checks and procedures, back-up and disaster recov-
ery of any local databases and validation of data
manipulation. The chief investigator, or where required,
a nominated designee of the sponsor, will carry out
monitoring of trial data as an ongoing activity. Entries
on Case Report Forms (CRFs) will be verified by inspec-
tion against the source data. A sample of CRFs (10% or
as per the study risk assessment) will be checked on a
regular basis for verification of all entries made. In
addition the subsequent capture of the data on the trial
database will be checked. Where corrections are re-
quired these will carry a full audit trail and justification.
Harms A side effect of physical activity for people with
T1DM is changes in blood glucose levels, above or below
normal, causing unfavourable symptoms. Hypoglycaemia
is when blood glucose levels drop too low and hypergly-
caemia is where blood glucose levels spike too high. The
hypoglycaemic and hyperglycaemic risks in this research
are no more severe than expected for the participant’s
condition (e.g. as a side effect of insulin treatment). Fur-
thermore, the physical activity encouraged through this
intervention is not of a high enough intensity or a long
enough duration to be deemed dangerous or high-risk to
children (the proposed modifications to physical activity
levels are in accordance with published guidelines for
paediatric T1DM [42]). However, if there is consider-
able exacerbation (increase in occurrences or severity
compared to before participation in the intervention)
of episodes of hypoglycaemia and/or hyperglycaemia
(blood glucose >14 mmol/l), then the participant will
be asked to discontinue their use of the intervention,
re-establish their previous daily routine and seek
medical advice.
Adverse events will be classified on the basis of severe
hypoglycaemia or hyperglycaemia, or any other injury or
incident believed to be caused by participation in the
STAK-D intervention. All information pertaining to ad-
verse events noted by the researcher during the study
will be listed by subject, detailing the episode date and
time of onset and date and time of resolution. The onset
of adverse events will be shown relative (in number of
min/h/days) to the time of the highest bout of physical
activity.
Dissemination A research paper will report the primary
outcome measures. The results will be disseminated
regardless of the magnitude or direction of effect.
The study results will also be disseminated to the
clinical teams in the participating centres and to the
participants.
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Post-trial care
Archiving Study-related documents will be archived at
the lead institution, on behalf of the NHS trust study
sponsor, at the end of the study for at least 10 years and
in line with all relevant legal and statutory requirements.
Roles and responsibilities
Trial Management Group The sponsor is the lead or-
ganisation where the research is to take place; Nottingham
University Hospitals (NUH) NHS Trust will act as sponsor
for this study (NUH NHS Trust). NUH NHS Trust will
act as guarantor for the research, ensuring that it complies
with standards of GCP. The chief investigator (HB) has
overall responsibility for the study, supported by CG and
all other team members. An appointed researcher will be
responsible for the daily monitoring and management,
reporting directly to HB. The two study site principal in-
vestigators (TR, JG) will oversee the identification of po-
tential participants as well as providing expert advice
during the study and the analysis and interpretation of the
results. BG is the study statistician.
Discussion
Among physical activity and exercise interventions for
young people with T1DM to date, most have neglected
lifestyle physical activity in favour of structured aerobic
or resistance exercise training, few have been under-
pinned by psychological theory of behaviour change, lit-
tle attention has been given to potential psychological
outcomes and technology-based interventions have been
scarce [11]. The current feasibility trial will provide data
to inform a larger trial, if required, to test whether the
STAK-D programme can promote self-efficacy for phys-
ical activity in children with T1DM.
The study aims to help children with T1DM and their
families, and ultimately to reduce NHS costs, through
possible reductions in the use of NHS services in the
longer term as children with T1DM will lead a healthier,
more active lifestyle and have better managed diabetes
in the long term. If feasible, we hope that STAK-D will
be disseminated nationally as a low-cost physical activity
promotion programme to support self-management of
paediatric T1DM.
Trial status
The trial was proposed at the time of original submis-
sion. Recruitment is ongoing at the time of revisions be-
ing submitted.
Endnote
1Reference to parent refers to parent and/or carer
throughout.
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